Latest News for NUWE
Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript
MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Nuwellis (NASDAQ: NUWE - Get Free Report) is expected to release its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Nuwellis to post earnings of ($1.56) per share and revenue of $2.31 million for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page
MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy.
MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NUWE.
U.S. House Trading
No House trades found for NUWE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.